Study Findings:
Epivir, a long-used anti-HIV drug, appears to be the first effective long-term treatment for patients with advanced liver disease caused by hepatitis B virus.
Researchers found Epivir (3TC) halved the risk of liver failure and the chance the disease would develop into liver cancer.
Of those who received Epivir, about 8% saw their liver disease get […]
Study Findings:
Only 8% of lamivudine-treated patients had defined events indicating disease progression in advanced chronic hepatitis B as compared with 18% of patients receiving placebo
3% of the lamivudine group saw an increase in the Child-Pugh score (assesses liver function), compared with 9% of those patients on placebo
Hepatocellular carcinoma (liver cancer) occurred in 4% of lamivudine […]
Study Findings:
People receiving the hepatitis B vaccination had a 3x greater risk of developing MS over the following three years than those not inoculated.